Last $216.13 USD
Change Today -2.05 / -0.94%
Volume 1.5M
ACT On Other Exchanges
Symbol
Exchange
Berlin
New York
Mexico
As of 8:04 PM 07/21/14 All times are local (Market data is delayed by at least 15 minutes).

actavis plc (ACT) Snapshot

Open
$217.17
Previous Close
$218.18
Day High
$218.17
Day Low
$215.68
52 Week High
02/26/14 - $230.77
52 Week Low
07/25/13 - $124.45
Market Cap
57.3B
Average Volume 10 Days
1.7M
EPS TTM
$2.76
Shares Outstanding
265.1M
EX-Date
--
P/E TM
78.3x
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTAVIS PLC (ACT)

actavis plc (ACT) Related Businessweek News

View More BusinessWeek News

actavis plc (ACT) Details

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians’ offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.

19,200 Employees
Last Reported Date: 02/25/14
Founded in 1983

actavis plc (ACT) Top Compensated Officers

Executive Chairman
Total Annual Compensation: $2.6M
Chief Financial Officer of Global
Total Annual Compensation: $557.3K
Chief Operating Officer
Total Annual Compensation: $639.5K
Executive Vice President of Commercial - Nort...
Total Annual Compensation: $557.7K
Compensation as of Fiscal Year 2013.

actavis plc (ACT) Key Developments

Actavis Files Abbreviated New Drug Application for Pregnancy Nausea; Duchesnay Files Suit Against Actavis plc

Actavis plc announced that it has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking approval to market Doxylamine Succinate and Pyridoxine Hydrochloride Delayed-release tablets, 10 mg/10 mg. The stock is steady after hours following a 0.5% regular-session gain. Actavis' ANDA product is a generic version of Duchesnay Inc.'s Diclegis. Duchesnay Inc. and Duchesnay USA Inc., filed suit against Actavis plc on July 10, 2014, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. Patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Actavis Plans to Close its Earth City Facilities

Days after closing on its acquisition of Forest Laboratories Inc., Actavis has announced to its employees a plan to close its Earth City facilities, a decision that will impact nearly 200 employees. The closing of the facility will be effective in June 2015, and approximately 200 employees involved in distribution/logistics, packaging, resource planning, quality purchasing, information technology, research and development, human resources, finance, and sales and marketing will be affected. Following a request for comment from Actavis officials, they issued a statement saying 190 employees in St. Louis would be impacted by the facility closures. However, employees in the company's St. Louis regional sales organization will not be impacted.

Pharmathen Signs Co-Operation Agreement with Actavis for Sale of Two Sustained-Release Injectable Drugs Internationally

Pharmathen has signed a co-operation agreement with Actavis (US) under which two sustained-release injectable drugs, used in the treatment of acromegaly and schizophrenia, including long-acting injectable technology developed by the former, will be sold internationally by the latter. The agreement means that from September, Pharmathen products made at its Rhodes factory will start to be used as part of the agreement.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACT:US $216.13 USD -2.05

ACT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Allergan Inc/United States $171.14 USD +3.74
Astellas Pharma Inc ¥1,404 JPY +22.00
Covidien PLC $88.53 USD 0.00
Shire PLC 4,911 GBp -60.00
Valeant Pharmaceuticals International Inc C$134.67 CAD +3.85
View Industry Companies
 

Industry Analysis

ACT

Industry Average

Valuation ACT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.0x
Price/Book 4.0x
Price/Cash Flow 103.8x
TEV/Sales 5.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTAVIS PLC, please visit www.actavis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.